About Genmab A/S
https://www.genmab.comGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
CEO
Jan van de Winkel
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-05-01 | Forward | 5:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
Guggenheim
Buy
William Blair
Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ORBIS ALLAN GRAY LTD
Shares:11.08M
Value:$391.5M
ALLIANCEBERNSTEIN L.P.
Shares:10.95M
Value:$387.11M
BLACKROCK INC.
Shares:5.08M
Value:$179.55M
Summary
Showing Top 3 of 298
About Genmab A/S
https://www.genmab.comGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.02B ▼ | $505M ▼ | $401M ▼ | 39.24% ▲ | $0.65 ▼ | $503M ▼ |
| Q2-2025 | $5.86B ▲ | $3.22B ▲ | $2.13B ▲ | 36.32% ▲ | $3.45 ▲ | $2.84B ▲ |
| Q1-2025 | $715M ▼ | $485M ▼ | $195M ▼ | 27.27% ▼ | $0.31 ▼ | $265M ▼ |
| Q4-2024 | $6.44B ▲ | $3.94B ▲ | $3.85B ▲ | 59.7% ▲ | $5.99 ▲ | $2.35B ▲ |
| Q3-2024 | $5.54B | $3.17B | $1.27B | 22.85% | $1.95 | $2.2B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.41B ▼ | $7.02B ▼ | $1.27B ▼ | $5.75B ▼ |
| Q2-2025 | $18.37B | $40.96B | $7.36B | $33.6B |
| Q1-2025 | $18.37B ▼ | $40.96B ▼ | $7.36B ▼ | $33.6B ▼ |
| Q4-2024 | $21.1B ▲ | $45.81B ▲ | $9.11B ▲ | $36.7B ▲ |
| Q3-2024 | $17.32B | $39.66B | $7.74B | $31.92B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $482M ▼ | $536M ▲ | $-54M ▼ | $-21M ▲ | $465M ▲ | $534M ▲ |
| Q2-2025 | $2.68B ▲ | $392.9M ▼ | $164.76M ▲ | $-2.57B ▼ | $-2.05B ▼ | $329.53M ▼ |
| Q1-2025 | $1.66B ▲ | $1.95B ▲ | $-292.16M ▼ | $-88.33M ▼ | $1.62B ▲ | $1.75B ▲ |
| Q4-2024 | $445.44M ▼ | $326.44M ▼ | $113.98M ▼ | $40.68M ▲ | $425.44M ▼ | $299.45M ▼ |
| Q3-2024 | $1.72B | $2.03B | $224M | $-276M | $2.01B | $1.99B |
CEO
Jan van de Winkel
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-05-01 | Forward | 5:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
Guggenheim
Buy
William Blair
Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ORBIS ALLAN GRAY LTD
Shares:11.08M
Value:$391.5M
ALLIANCEBERNSTEIN L.P.
Shares:10.95M
Value:$387.11M
BLACKROCK INC.
Shares:5.08M
Value:$179.55M
Summary
Showing Top 3 of 298